<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21060" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>HIV Encephalitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Daliparty</surname>
            <given-names>Vasudev Malik</given-names>
          </name>
          <aff>Sri B.M. Patil Medical College Hospital &#x00026; Research Centre</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Balasubramanya</surname>
            <given-names>Rashmi</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vasudev Malik Daliparty declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rashmi Balasubramanya declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21060.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>HIV encephalitis is a complication of HIV infection, which presents with neurocognitive dysfunction of varying severity. Almost half of HIV-infected patients suffer from this condition during their illness. Prompt administration of antiretroviral therapy is the most effective treatment choice for this condition. This activity reviews the pathophysiology, clinical presentation, and treatment options for HIV encephalitis and highlights the interprofessional team's role in evaluating and optimally managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology and pathophysiological processes involved in the development of HIV encephalitis.</p></list-item><list-item><p>Assess&#x000a0;the clinical presentation of a patient with HIV encephalitis.</p></list-item><list-item><p>Apply&#x000a0;the diagnostic modalities and treatment options for HIV encephalitis.</p></list-item><list-item><p>Communicate&#x000a0;the importance of collaboration among the interprofessional team in identifying and appropriately managing patients with HIV encephalitis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21060&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21060">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21060.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>HIV encephalitis, also referred to as HIV-associated neurological disorder (HAND), includes a range of neurocognitive defects of varying severity following HIV infection. The clinical presentation of this condition varies from asymptomatic or minor neurocognitive impairment to severe dementia. HIV encephalopathy, also known as AIDS-dementia complex, lies at the most severe end of this spectrum. The diagnosis is based on a combination of clinical neuropsychiatric evaluation and radiological studies. Prompt and effective administration of antiretroviral therapy (ART) is the most effective therapy in managing HIV encephalitis.</p>
      </sec>
      <sec id="article-21060.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact mechanism by which HIV infection leads to HIV encephalitis is not entirely clear.<xref ref-type="bibr" rid="article-21060.r1">[1]</xref> A genetic basis for HIV encephalitis has also been studied, with the presence of an E4 allele for <italic toggle="yes">apoE</italic> being associated with an increased risk of neurocognitive damage.<xref ref-type="bibr" rid="article-21060.r2">[2]</xref>&#x000a0;However, some studies have demonstrated no proven association between the presence or absence of genetic polymorphisms and the prevalence of HIV encephalitis.<xref ref-type="bibr" rid="article-21060.r3">[3]</xref> A low CD4 count and high plasma viral load are the key factors determining the development of HIV encephalitis. The patient's age at seroconversion is another important determinant, with patients of older age groups having an increased prevalence of cognitive deficits compared to younger populations. The presence of various comorbidities in older age groups, such as insulin resistance and obesity, also contributes to an extent.</p>
      </sec>
      <sec id="article-21060.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The neurological disease spectrum in patients with HIV infection can be attributed to various causes, such as opportunistic infections of the central nervous system (CNS), polyneuropathies, spinal cord pathologies, and HIV encephalitis. In the United States, where antiretroviral therapy is widely accessible, the neurologic symptoms in patients with HIV disease are often due to HIV encephalitis. On the other hand, in developing countries where access to HIV treatment still demands improvement, neurologic deterioration is often implicated in opportunistic CNS infections such as toxoplasmosis and cryptococcosis, to name a few. No gender preponderance has been observed relative to HIV encephalitis.</p>
        <p>There has been a significant decrease in the severity of HIV encephalitis over the years, owing to the advent and widespread usage of antiretroviral therapy (ART).<xref ref-type="bibr" rid="article-21060.r4">[4]</xref> But, even in the setting of ART, almost half of HIV-infected patients have been shown to suffer from mild to moderate neurocognitive dysfunction during their illness.<xref ref-type="bibr" rid="article-21060.r5">[5]</xref><xref ref-type="bibr" rid="article-21060.r6">[6]</xref>&#x000a0;However, the presence of other comorbidities such as substance abuse, diabetes, hypertension, and the effects of aging prevents us from getting a clearer estimate of the degree of cognitive deficits that can be exclusively attributed to HIV encephalitis.</p>
      </sec>
      <sec id="article-21060.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Direct damage of central nervous system tissue due to HIV combined with activated immune responses to infection has been implicated in causing the neurocognitive decline associated with HIV encephalitis.&#x000a0;HIV infection results in rapid virus seeding in various body premises, including CNS tissues, which are usually asymptomatic. Following infection with HIV, monocytes circulating in the blood migrate to the brain after traversing the blood-brain barrier, thus enabling HIV to gain access to the central nervous system. The entry of HIV into brain tissue through brain endothelium is believed to be aided by the induction of vascular cell adhesion molecule 1 (VCAM-1) and E-selectin. Though the direct impact of HIV on neurocognitive dysfunction after further development of distinct genetic sequences has been studied, the more significant impact has been attributed to the indirect immune pathways triggered after viral entry into brain tissue.<xref ref-type="bibr" rid="article-21060.r7">[7]</xref></p>
        <p>The release of monocyte-derived cytokines such as interleukin-1, tumor necrosis factor-&#x003b1;, and transforming growth factor-&#x003b2;, which trigger neurotoxic changes, is believed to be the more damaging entity in the pathophysiology of HIV encephalopathy.<xref ref-type="bibr" rid="article-21060.r8">[8]</xref> Increased levels of monocytic chemotactic protein-1 in cerebrospinal fluid (CSF) have been shown to correlate with the severity of HIV encephalopathy.</p>
        <p>The compartmentalization of HIV infection in the CNS also plays a particularly important role in developing HIV encephalitis. After the virus's initial development from the circulating CD4 cells, in later stages of infection, CSF viral replication occurs independently of plasma viral replication. A change in the tropism of the CNS viruses in the later stages of the infection also worsens the severity of the illness.&#x000a0;</p>
        <p>Several factors determine the neurological deterioration in HIV encephalitis. The production of neurotoxic HIV proteins, uncontrolled viral replication in brain tissue, and immune activation are underlying factors controlling the rate of neurological decline.<xref ref-type="bibr" rid="article-21060.r9">[9]</xref></p>
      </sec>
      <sec id="article-21060.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Although HIV encephalitis can involve any part of the brain, pathologic changes such as pallor and gliosis are most often noted in the basal ganglia and nigrostriatal areas in the initial stages of the illness. These changes can be identified as early as within 1 year of the development of HIV encephalitis.<xref ref-type="bibr" rid="article-21060.r10">[10]</xref> Later stages involve diffuse cerebral involvement, particularly in the temporal and frontal regions. In these areas, microglial cells are stimulated by the virus to fuse and form multinucleated microglial cells. Perivascular infiltrates are often seen. This resultant subcortical microglial nodule encephalitis is pathognomic for HIV encephalitis.</p>
        <p>The effect of HIV on astrocytes and oligodendrocytes has also been identified, but the pathologic significance of this cellular affliction has not been clearly demonstrated.<xref ref-type="bibr" rid="article-21060.r11">[11]</xref></p>
      </sec>
      <sec id="article-21060.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>History</bold>
</p>
        <p>The classical presentation of HIV encephalitis presents in a waxing and waning pattern rather than a progressive deterioration, as noted in conditions such as Alzheimer disease. Though HIV encephalitis is usually considered a late manifestation of HIV disease, it has also been known to occur in patients with CD4 counts of more than 350 cells/&#x003bc;L. The elucidation of symptoms that show a cognitive decline from the previous level indicates the presence of HIV encephalitis. Subcortical deficits such as psychomotor retardation, decreased concentration, and decreased attention are often the hallmark of the presentation of this disease. An increase in forgetfulness and difficulty in performing complex tasks may also be noted often. Later stages of the disease may present with bowel and/or bladder complaints.</p>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>Motor abnormalities such as tremors, gait, and balance disturbances are often demonstrated along with increased deep tendon reflexes and muscle tone. Mini-Mental Status Examination (MMSE) is done to objectively establish the cognitive function of individuals and compare it to earlier scores to check for deterioration.<xref ref-type="bibr" rid="article-21060.r12">[12]</xref>&#x000a0;The absence of cortical dysfunction signs such as agnosia, apraxia, and aphasia points away from the diagnosis of cortical dementia, such as Alzheimer disease, and substantiates the diagnosis of HIV encephalitis.</p>
        <p>Clinical staging of HIV encephalitis is based mainly on the combined neurocognitive and functional status of the patient. The 3 main stages are namely, asymptomatic (neurocognitive status of 1 SD below mean in 2 cognitive domains with no impairments in activities of daily living), mild (neurocognitive status of 1 SD below mean in 2 cognitive domains with impairments in activities of daily living) and HIV-associated dementia (neurocognitive status of 2 SD below mean in 2 cognitive domains with notable impairments in activities of daily living).</p>
      </sec>
      <sec id="article-21060.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Lab Studies</bold>
</p>
        <p>Cerebrospinal fluid (CSF) analysis by lumbar puncture plays an important role in evaluation. An increase in CSF protein, cell count, and the identification of HIV RNA in CSF are all noted but are often non-specific findings related to HIV encephalopathy. In patients with HIV infection presenting with neurologic problems, CSF analysis helps rule out other opportunistic infections. The role of HIV culture in cerebral tissue samples of patients with HIV encephalitis has been extensively studied, with HIV cultures obtained from nerve, CSF, and brain tissues yielding positive results. However, this culture positivity has been noted in all the stages of HIV infection and does not correlate with the presence or absence of neurological symptoms or signs. Testing for CSF HIV viral levels and drug resistance is not routinely performed. An extensive metabolic panel needs to be undertaken in these patients to rule out conditions related to thyroid disease, folate, B12, syphilis, and hepatic disorders, which can present with a similar neurologic presentation.&#x000a0;</p>
        <p>
<bold>Radiology</bold>
</p>
        <p>Neuroimaging studies in patients suffering from HIV encephalopathy usually show cerebral atrophy on CT or MRI. In advanced stages of the disease, on T2-weighted sequences, multiple symmetric foci of hyperintense, non-enhancing lesions are seen predominantly in a subcortical distribution.<xref ref-type="bibr" rid="article-21060.r13">[13]</xref></p>
      </sec>
      <sec id="article-21060.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The only proven option in managing HIV encephalitis, HART has proved to be of benefit in patients with HIV encephalitis, with significant improvements demonstrated in neuropsychiatric and cognitive test scores. The treatment has been shown to decrease and effectively reverse the pathologic damage caused by HIV clinically and radiographically.&#x000a0;ART also helps to delay or prevent the onset of neurocognitive impairment in patients with HIV disease.<xref ref-type="bibr" rid="article-21060.r14">[14]</xref>&#x000a0;The effectiveness of ART in these patients has led to a decrease in the prevalence of severity of HIV encephalopathy, with a notable decrease in the number of cases of AIDS-dementia complex and an increased prevalence in the milder presentation of this disease.<xref ref-type="bibr" rid="article-21060.r15">[15]</xref>&#x000a0;ART has shown to be of clear benefit in patients presenting with HIV-associated dementia, whereas patients with milder cognitive impairment have not shown any significant improvement.<xref ref-type="bibr" rid="article-21060.r16">[16]</xref></p>
        <p>Drug regimens that have higher CNS penetrance have been proven to be of better effect in managing patients with HIV encephalitis.<xref ref-type="bibr" rid="article-21060.r17">[17]</xref> Tailoring treatment after considering both the CNS penetrance effect and the individual patient profile can provide optimum patient benefit. Efavirenz is usually not preferred in neurocognitive disorders owing to its many neuropsychiatric adverse effects.</p>
        <p>In patients diagnosed with HIV-associated dementia in whom initiation of ART is planned, the preferred regimen is tenofovir, dolutegravir plus emtricitabine, or a combination of lamivudine, abacavir plus dolutegravir.&#x000a0;</p>
        <p>Drugs such as lithium, memantine, and minocycline have not proven beneficial in patients with HIV encephalitis.<xref ref-type="bibr" rid="article-21060.r18">[18]</xref><xref ref-type="bibr" rid="article-21060.r19">[19]</xref><xref ref-type="bibr" rid="article-21060.r20">[20]</xref></p>
      </sec>
      <sec id="article-21060.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses for&#x000a0;HIV encephalitis include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Primary CNS lymphoma:&#x000a0;</bold>This can also present with cognitive decline, memory loss, and motor symptoms such as hemiparesis. However, there are usually constitutional symptoms such as night sweats and fever. Imaging helps in differentiating between the&#x000a0;2 entities. Primary CNS lymphoma presents as mass lesions predominantly in the periventricular regions.</p>
          </list-item>
          <list-item>
            <p><bold>Progressive multifocal leukoencephalopathy (PML):</bold>&#x000a0;This is a rapidly progressive demyelinating disorder seen in immunosuppressed patients. Caused by the&#x000a0;JC virus, it can present with hemiparesis, ataxia, and memory loss. MRI shows bilateral, asymmetric foci of demyelination without mass effect in the periventricular and subcortical regions.</p>
          </list-item>
          <list-item>
            <p><bold>Opportunistic infections:</bold>&#x000a0;These include cryptococcosis and toxoplasmosis, which can be differentiated from HIV encephalitis by the associated clinical features, such as seizures. On imaging, both cryptococcus and toxoplasmosis show focal enhancing lesions with a mass effect. Cryptococcus can also present as meningitis, and toxoplasmosis leads to brain abscess.</p>
          </list-item>
          <list-item>
            <p><bold>Nutritional deficiencies:</bold>&#x000a0;Vitamin B12 and folate deficiency disorders must be ruled out.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21060.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Without the administration of ART, the AIDS-dementia complex can be fatal within 1 year. ART helps slow the disease's progression and leads to increased life expectancy in patients. Older patient age and poor adherence to ART are the factors that are usually responsible for poorer outcomes in these patients.<xref ref-type="bibr" rid="article-21060.r21">[21]</xref>&#x000a0;The type of ART administration also determines the mode and severity of neuropsychiatric symptom patterns. Some studies have demonstrated that the use of combination ART compared to a single drug ART has shown improvements in visuospatial orientation and attention but a regression in learning efficiency.<xref ref-type="bibr" rid="article-21060.r22">[22]</xref></p>
        <p>The presence of even asymptomatic or mild neurocognitive impairment at baseline is an indicator of future neurologic decline. Some studies have demonstrated that even in this era of ART, the presence of neurocognitive deficits in a patient with HIV infection is a marker for increased mortality.<xref ref-type="bibr" rid="article-21060.r23">[23]</xref></p>
      </sec>
      <sec id="article-21060.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The implementation of ART usage primarily determines the course of illness and complications in patients with HIV encephalitis. A rare condition termed CNS viral escape syndrome has been demonstrated in ART-treated patients. This condition presents with new-onset neurocognitive defects, and lab studies demonstrate high CSF viral replication despite low plasma viral levels.<xref ref-type="bibr" rid="article-21060.r24">[24]</xref></p>
      </sec>
      <sec id="article-21060.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>ART administration should be considered promptly after the diagnosis of HIV disease owing to its beneficial effect. Emphasis should be placed on the importance of adherence to ART, potentially leading to significantly better patient outcomes.</p>
      </sec>
      <sec id="article-21060.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to keep in mind about HIV&#x000a0;encephalitis are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>The initial stages of HIV encephalopathy are often similar in presentation to depression, fatigue, or Alzheimer disease and should be carefully differentiated.</p>
          </list-item>
          <list-item>
            <p>A baseline MMSE should be established for all patients in whom HIV infection has been diagnosed.</p>
          </list-item>
          <list-item>
            <p>CSF analysis following lumbar puncture plays a crucial role in ruling out the diagnoses of opportunistic infections.</p>
          </list-item>
          <list-item>
            <p>Patients with HIV encephalopathy demonstrate increased sensitivity to neuroleptic drugs; therefore, patients with HIV encephalopathy who receive these drugs should be monitored carefully, as they have an increased risk of developing extrapyramidal side effects.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21060.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>When confronted with a patient with HIV encephalitis, an interprofessional healthcare team approach is best suited to driving better patient outcomes. This team includes clinicians, specialists, pharmacists, and nurses, collaborating and communicating across individual disciplines to ensure optimal care. A consultation with an infectious disease specialist for prompt and efficient ART administration and a neurological consultation for careful evaluation and monitoring of neurocognitive functioning provide the most benefit in managing patients with HIV encephalitis. ART administration is the most important factor determining outcomes in patients suffering from HIV encephalitis.<xref ref-type="bibr" rid="article-21060.r25">[25]</xref></p>
      </sec>
      <sec id="article-21060.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21060&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21060">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/hiv-encephalitis-hiv-associated-neurological-disorder-hand/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21060">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21060/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21060">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21060.s17">
        <title>References</title>
        <ref id="article-21060.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grant</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Deutsch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Vaida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Marcotte</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Gelman</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Morgello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>McCutchan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Abramson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gamst</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fennema-Notestine</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>RK</given-names>
              </name>
              <collab>CHARTER Group</collab>
            </person-group>
            <article-title>Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline.</article-title>
            <source>Neurology</source>
            <year>2014</year>
            <month>Jun</month>
            <day>10</day>
            <volume>82</volume>
            <issue>23</issue>
            <fpage>2055</fpage>
            <page-range>2055-62</page-range>
            <pub-id pub-id-type="pmid">24814848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wendelken</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Jahanshad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Busovaca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Coppola</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rankin</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Milanini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wojta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nir</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Gutman</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Valcour</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>ApoE &#x003b5;4 Is Associated With Cognition, Brain Integrity, and Atrophy in HIV Over Age 60.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2016</year>
            <month>Dec</month>
            <day>01</day>
            <volume>73</volume>
            <issue>4</issue>
            <fpage>426</fpage>
            <page-range>426-432</page-range>
            <pub-id pub-id-type="pmid">27228100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Service</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Shapshak</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Freimer</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults.</article-title>
            <source>Am J Med Genet B Neuropsychiatr Genet</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>159B</volume>
            <issue>6</issue>
            <fpage>669</fpage>
            <page-range>669-83</page-range>
            <pub-id pub-id-type="pmid">22628157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <collab>Antiretroviral Therapy Cohort Collaboration</collab>
            <article-title>Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.</article-title>
            <source>Lancet</source>
            <year>2008</year>
            <month>Jul</month>
            <day>26</day>
            <volume>372</volume>
            <issue>9635</issue>
            <fpage>293</fpage>
            <page-range>293-9</page-range>
            <pub-id pub-id-type="pmid">18657708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heaton</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Deutsch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Casaletto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Marquine</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Vaida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Marcotte</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>McCutchan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Gelman</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Morgello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Abramson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gamst</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Fennema-Notestine</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>I</given-names>
              </name>
              <collab>CHARTER Group</collab>
            </person-group>
            <article-title>Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.</article-title>
            <source>Clin Infect Dis</source>
            <year>2015</year>
            <month>Feb</month>
            <day>01</day>
            <volume>60</volume>
            <issue>3</issue>
            <fpage>473</fpage>
            <page-range>473-80</page-range>
            <pub-id pub-id-type="pmid">25362201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheppard</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Iudicello</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bondi</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Massman</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Elevated rates of mild cognitive impairment in HIV disease.</article-title>
            <source>J Neurovirol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>576</fpage>
            <page-range>576-84</page-range>
            <pub-id pub-id-type="pmid">26139019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGuire</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Douglas</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Kolson</surname>
                <given-names>DL</given-names>
              </name>
              <collab>CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) group</collab>
            </person-group>
            <article-title>Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.</article-title>
            <source>J Neurovirol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>439</fpage>
            <page-range>439-48</page-range>
            <pub-id pub-id-type="pmid">25776526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>MCE</given-names>
              </name>
              <name>
                <surname>Ayyavoo</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Human immunodeficiency virus type 1 (HIV-1)-mediated neuroinflammation dysregulates neurogranin and induces synaptodendritic injury.</article-title>
            <source>J Neuroinflammation</source>
            <year>2018</year>
            <month>Apr</month>
            <day>27</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>126</fpage>
            <pub-id pub-id-type="pmid">29703241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marquine</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Umlauf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rooney</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Fazeli</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Gouaux</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Paul Woods</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>DJ</given-names>
              </name>
              <collab>HIV Neurobehavioral Research Program (HNRP) Group</collab>
            </person-group>
            <article-title>The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2014</year>
            <month>Feb</month>
            <day>01</day>
            <volume>65</volume>
            <issue>2</issue>
            <fpage>190</fpage>
            <page-range>190-7</page-range>
            <pub-id pub-id-type="pmid">24442225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langford</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Larrea</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Masliah</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Changing patterns in the neuropathogenesis of HIV during the HAART era.</article-title>
            <source>Brain Pathol</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>195</fpage>
            <page-range>195-210</page-range>
            <pub-id pub-id-type="pmid">12744473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kadiu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kraft-Terry</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Schlautman</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Ciborowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Volsky</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Gendelman</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>HIV-1-infected astrocytes and the microglial proteome.</article-title>
            <source>J Neuroimmune Pharmacol</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>173</fpage>
            <page-range>173-86</page-range>
            <pub-id pub-id-type="pmid">18587649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nir</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Jahanshad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Busovaca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wendelken</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nicolas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Valcour</surname>
                <given-names>VG</given-names>
              </name>
            </person-group>
            <article-title>Mapping white matter integrity in elderly people with HIV.</article-title>
            <source>Hum Brain Mapp</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>975</fpage>
            <page-range>975-92</page-range>
            <pub-id pub-id-type="pmid">23362139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valcour</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chiao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wendelken</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Screening for cognitive impairment in human immunodeficiency virus.</article-title>
            <source>Clin Infect Dis</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>53</volume>
            <issue>8</issue>
            <fpage>836</fpage>
            <page-range>836-42</page-range>
            <pub-id pub-id-type="pmid">21921226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hellmuth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Spudich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Valcour</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Cognitive Impairment and Persistent CNS Injury in Treated HIV.</article-title>
            <source>Curr HIV/AIDS Rep</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>209</fpage>
            <page-range>209-17</page-range>
            <pub-id pub-id-type="pmid">27188299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Skolasky</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Seaberg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Munro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ragin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>Jan</month>
            <day>26</day>
            <volume>86</volume>
            <issue>4</issue>
            <fpage>334</fpage>
            <page-range>334-40</page-range>
            <pub-id pub-id-type="pmid">26718568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simioni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cavassini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Annoni</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rimbault Abraham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bourquin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schiffer</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Calmy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chave</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Giacobini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hirschel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Du Pasquier</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Cognitive dysfunction in HIV patients despite long-standing suppression of viremia.</article-title>
            <source>AIDS</source>
            <year>2010</year>
            <month>Jun</month>
            <day>01</day>
            <volume>24</volume>
            <issue>9</issue>
            <fpage>1243</fpage>
            <page-range>1243-50</page-range>
            <pub-id pub-id-type="pmid">19996937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ellis</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vaida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Haubrich</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Best</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Umlauf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cherner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ballard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Jay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McCutchan</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder.</article-title>
            <source>Clin Infect Dis</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>58</volume>
            <issue>7</issue>
            <fpage>1015</fpage>
            <page-range>1015-22</page-range>
            <pub-id pub-id-type="pmid">24352352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Decloedt</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Howells</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Casson-Crook</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lesosky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koutsilieri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lovestone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maartens</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Joska</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled trial of lithium.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>95</volume>
            <issue>46</issue>
            <fpage>e5401</fpage>
            <pub-id pub-id-type="pmid">27861379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schifitto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Navia</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Yiannoutsos</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ernst</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jarvik</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kolson</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nath</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shriver</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Millar</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Colquhoun</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lenkinski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>SA</given-names>
              </name>
              <collab>Adult AIDS Clinical Trial Group (ACTG) 301</collab>
              <collab>700 Teams</collab>
              <collab>HIV MRS Consortium</collab>
            </person-group>
            <article-title>Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.</article-title>
            <source>AIDS</source>
            <year>2007</year>
            <month>Sep</month>
            <day>12</day>
            <volume>21</volume>
            <issue>14</issue>
            <fpage>1877</fpage>
            <page-range>1877-86</page-range>
            <pub-id pub-id-type="pmid">17721095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakasujja</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Miyahara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Musisi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Katabira</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ronald</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment.</article-title>
            <source>Neurology</source>
            <year>2013</year>
            <month>Jan</month>
            <day>08</day>
            <volume>80</volume>
            <issue>2</issue>
            <fpage>196</fpage>
            <page-range>196-202</page-range>
            <pub-id pub-id-type="pmid">23269596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sevigny</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>McDermott</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Schifitto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Conant</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Selnes</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>McClernon</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Palumbo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kieburtz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Riggs</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Marder</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>LG</given-names>
              </name>
            </person-group>
            <article-title>An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection.</article-title>
            <source>Arch Neurol</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-102</page-range>
            <pub-id pub-id-type="pmid">17210815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brew</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex.</article-title>
            <source>AIDS</source>
            <year>2004</year>
            <month>Jan</month>
            <day>01</day>
            <volume>18 Suppl 1</volume>
            <fpage>S75</fpage>
            <page-range>S75-8</page-range>
            <pub-id pub-id-type="pmid">15075501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vivithanaporn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Heo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gamble</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krentz</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Hoke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Power</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study.</article-title>
            <source>Neurology</source>
            <year>2010</year>
            <month>Sep</month>
            <day>28</day>
            <volume>75</volume>
            <issue>13</issue>
            <fpage>1150</fpage>
            <page-range>1150-8</page-range>
            <pub-id pub-id-type="pmid">20739646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peluso</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ferretti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Boschini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gissl&#x000e9;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Angoff</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Cinque</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Spudich</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.</article-title>
            <source>AIDS</source>
            <year>2012</year>
            <month>Sep</month>
            <day>10</day>
            <volume>26</volume>
            <issue>14</issue>
            <fpage>1765</fpage>
            <page-range>1765-74</page-range>
            <pub-id pub-id-type="pmid">22614889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21060.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lescure</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Omland</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Engsig</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Roed</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gerstoft</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pialoux</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kronborg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Obel</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study.</article-title>
            <source>Clin Infect Dis</source>
            <year>2011</year>
            <month>Jan</month>
            <day>15</day>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>235</fpage>
            <page-range>235-43</page-range>
            <pub-id pub-id-type="pmid">21288850</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
